ENDMC
MCID: END057
MIFTS: 68

Endometrial Cancer (ENDMC)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases

Aliases & Classifications for Endometrial Cancer

MalaCards integrated aliases for Endometrial Cancer:

Name: Endometrial Cancer 58 12 76 38 13 56 15
Endometrial Carcinoma 12 30 56 6 15 17 74
Endometrial Neoplasm 12 30 6 17
Malignant Neoplasm of Endometrium 12 74
Carcinoma, Endometrioid 45 74
Endometrioid Carcinoma 12 17
Endometrial Neoplasms 45 74
Endometrioid Carcinoma of Female Reproductive System 12
Primary Malignant Neoplasm of Endometrium 12
Endometrial Cancer, Susceptibility to 58
Endometrial Carcinoma, Somatic 58
Malignant Endometrial Neoplasm 12
Endometrial Cancer, Familial 58
Carcinoma of the Endometrium 12
Neoplasm of Endometrium 12
Carcinoma Endometrioid 56
Uterine Corpus Cancer 74
Tumor of Endometrium 12
Cancer, Endometrial 41
Endometrial Ca 12
Endmc 76

Characteristics:

HPO:

33
endometrial cancer:
Inheritance somatic mutation


Classifications:



Summaries for Endometrial Cancer

UniProtKB/Swiss-Prot : 76 Endometrial cancer: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

MalaCards based summary : Endometrial Cancer, also known as endometrial carcinoma, is related to lynch syndrome and adenocarcinoma. An important gene associated with Endometrial Cancer is MSH6 (MutS Homolog 6), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Peppermint and Megestrol acetate have been mentioned in the context of this disorder. Affiliated tissues include lymph node, uterus and testes, and related phenotypes are endometrial carcinoma and Decreased viability

Disease Ontology : 12 A endometrial cancer that is located in the tissue lining the uterus.

Wikipedia : 77 Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It... more...

Description from OMIM: 608089

Related Diseases for Endometrial Cancer

Diseases related to Endometrial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 350)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 33.4 CTNNB1 KRAS MLH3 MSH3 MSH6 MUTYH
2 adenocarcinoma 31.5 CDH1 CTNNB1 FGFR2 KRAS PTEN
3 carcinosarcoma 31.2 CTNNB1 KRAS PTEN
4 breast cancer 31.1 CASC2 CDH1 CTNNB1 FGFR2 GAS5 HOTAIR
5 familial adenomatous polyposis 31.1 CDH1 CTNNB1 KRAS MSH3 MSH6 MUTYH
6 adenoid cystic carcinoma 31.0 CDH1 CTNNB1 KRAS PTEN
7 uterine carcinosarcoma 30.9 CDH1 CTNNB1 FGFR2 PTEN
8 endometrial adenocarcinoma 30.9 CTNNB1 FGFR2 KRAS PTEN
9 colorectal cancer 30.9 CASC2 CDH1 CTNNB1 GAS5 HOTAIR KRAS
10 ovarian cancer 30.9 CDH1 CTNNB1 GAS5 HOTAIR KRAS LINC-ROR
11 mismatch repair cancer syndrome 30.8 CTNNB1 MSH6 PTEN
12 uterine anomalies 30.7 CDH1 CTNNB1 MSH6 PTEN
13 cervical cancer 30.7 CDH1 CTNNB1 GAS5 HOTAIR PTEN TUG1
14 squamous cell carcinoma 30.6 CDH1 CTNNB1 FGFR2 HOTAIR PTEN TUG1
15 gallbladder cancer 30.5 CDH1 HOTAIR KRAS LINC-ROR TUG1 UCA1
16 thyroid cancer 30.4 CASC2 CDH1 CTNNB1 GAS5 HOTAIR KRAS
17 myeloma, multiple 30.2 GAS5 HOTAIR KRAS TUG1 UCA1
18 pancreatic cancer 30.1 CASC2 CDH1 CTNNB1 GAS5 HOTAIR KRAS
19 melanoma 30.1 GAS5 HOTAIR LINC-ROR MIR200C PTEN UCA1
20 lung cancer 30.1 CASC2 CDH1 FGFR2 GAS5 HOTAIR KRAS
21 renal cell carcinoma, nonpapillary 30.0 CASC2 CDH1 GAS5 HOTAIR LINC-ROR MIR200C
22 uterine corpus endometrial carcinoma 12.3
23 ovarian endometrial cancer 12.1
24 fallopian tube endometrioid adenocarcinoma 11.5
25 polycystic ovary syndrome 11.4
26 colorectal cancer, hereditary nonpolyposis, type 5 11.4
27 high-grade neuroendocrine carcinoma of the corpus uteri 11.3
28 cervical endometrioid adenocarcinoma 11.2
29 cowden syndrome 1 11.1
30 endometrial transitional cell carcinoma 11.1
31 endometrial squamous cell carcinoma 11.1
32 endometrial adenosquamous carcinoma 11.1
33 endometrium carcinoma in situ 11.1
34 lynch syndrome i 11.1
35 precocious puberty, central, 1 11.1
36 polycystic ovary syndrome 1 11.1
37 precocious puberty, central, 2 11.1
38 female reproductive system disease 10.7 CDH1 CTNNB1 MSH6 PTEN
39 colonic disease 10.7 CDH1 CTNNB1 KRAS MSH6
40 colorectal adenocarcinoma 10.7 CDH1 CTNNB1 KRAS MSH6
41 respiratory system cancer 10.7 CDH1 CTNNB1 KRAS PTEN
42 reproductive system disease 10.7 CDH1 CTNNB1 PTEN
43 endocrine gland cancer 10.7 CDH1 CTNNB1 KRAS PTEN
44 colon adenocarcinoma 10.7 CDH1 CTNNB1 KRAS MSH6
45 intestinal disease 10.7 CDH1 CTNNB1 KRAS MSH6 MUTYH
46 gastric adenocarcinoma 10.7 CDH1 CTNNB1 FGFR2 HOTAIR KRAS PTEN
47 gastrointestinal system cancer 10.7 CDH1 CTNNB1 HOTAIR KRAS MSH6 MUTYH
48 male reproductive organ cancer 10.7 CDH1 CTNNB1 PTEN
49 large intestine cancer 10.7 CDH1 CTNNB1 KRAS MLH3 MSH3 MSH6
50 intrahepatic cholangiocarcinoma 10.7 CDH1 CTNNB1 FGFR2 KRAS TUG1

Graphical network of the top 20 diseases related to Endometrial Cancer:



Diseases related to Endometrial Cancer

Symptoms & Phenotypes for Endometrial Cancer

Human phenotypes related to Endometrial Cancer:

33
# Description HPO Frequency HPO Source Accession
1 endometrial carcinoma 33 HP:0012114

Clinical features from OMIM:

608089

GenomeRNAi Phenotypes related to Endometrial Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.55 KRAS
2 Decreased viability GR00106-A-0 9.55 KRAS
3 Decreased viability GR00221-A-1 9.55 CDH1 KRAS
4 Decreased viability GR00221-A-2 9.55 KRAS
5 Decreased viability GR00301-A 9.55 CDH1 FGFR2 KRAS MLH3
6 Decreased viability GR00342-S-1 9.55 FGFR2
7 Decreased viability GR00342-S-2 9.55 FGFR2
8 Decreased viability GR00342-S-3 9.55 FGFR2
9 Decreased viability GR00381-A-1 9.55 KRAS
10 Decreased viability GR00402-S-2 9.55 CDH1 FGFR2 KRAS MLH3

MGI Mouse Phenotypes related to Endometrial Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 CDH1 CTNNB1 FGFR2 KRAS MSH3 MSH6

Drugs & Therapeutics for Endometrial Cancer

Drugs for Endometrial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peppermint Approved Phase 4
2
Megestrol acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 595-33-5 11683
3
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 71-58-9
4
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2 28014-46-2
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
6
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
7 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
9 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Appetite Stimulants Phase 4,Phase 3,Phase 2,Phase 1
11 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
13
Megestrol Phase 4,Phase 3,Phase 2,Phase 1 3562-63-8 3080587 19090
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2
16
Medroxyprogesterone Phase 4,Phase 2,Phase 3,Not Applicable 520-85-4 10631
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Contraceptive Agents, Male Phase 4,Phase 2,Phase 3
19 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2
20 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Fluorodeoxyglucose F18 Phase 4,Phase 1,Phase 2,Not Applicable
22 taxane Phase 4,Phase 1,Not Applicable
23 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
25
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 38904 498142
26
Sargramostim Approved, Investigational Phase 3,Phase 1,Phase 2 123774-72-1, 83869-56-1
27
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
28
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
29
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
30
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
31
Sodium Citrate Approved, Investigational Phase 3,Phase 2 68-04-2
32
Levonorgestrel Approved, Investigational Phase 3,Phase 2,Not Applicable 797-63-7, 17489-40-6 13109
33
Methylene blue Approved, Investigational Phase 3,Not Applicable 61-73-4
34
Letrozole Approved, Investigational Phase 3,Phase 2,Not Applicable 112809-51-5 3902
35
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
36
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1 1380723-44-3
37
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
38
Epirubicin Approved Phase 3 56420-45-2 41867
39
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
40
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
41
Pembrolizumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1374853-91-4
42
Lenvatinib Approved, Investigational Phase 3,Phase 2,Phase 1 417716-92-8
43
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
44
Ifosfamide Approved Phase 3 3778-73-2 3690
45
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
46
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
47
Niraparib Approved, Investigational Phase 2, Phase 3,Phase 1 1038915-60-4 24958200
48
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 1 119413-54-6, 123948-87-8 60700
49
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
50
Exemestane Approved, Investigational Phase 3,Phase 2,Not Applicable 107868-30-4 60198

Interventional clinical trials:

(show top 50) (show all 767)
# Name Status NCT ID Phase Drugs
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Recruiting NCT03349463 Phase 4 Fluciclovine F18
4 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Recruiting NCT03423082 Phase 4 18F fluciclovine
5 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
6 Application of Tachosil During Lymphadenectomy Completed NCT03752606 Phase 4
7 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
8 Pharmacokinetics and Safety of Transdermal Megestrol Acetate Withdrawn NCT00163072 Phase 4 transdermal Megace
9 Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia Completed NCT02872818 Phase 4 17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
10 Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY Unknown status NCT02762214 Phase 3
11 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Unknown status NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
12 Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms Unknown status NCT01464697 Phase 3 Oral micronized progesterone;placebo
13 Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Unknown status NCT00925639 Phase 3 Isoflavone;Placebo
14 Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet. Unknown status NCT01414517 Phase 3
15 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
16 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
17 Atezolizumab Trial in Endometrial Cancer - AtTEnd Recruiting NCT03603184 Phase 3 Atezolizumab;Placebos;Paclitaxel;Carboplatin
18 VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients. Recruiting NCT03324958 Phase 3
19 Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer. Recruiting NCT03555422 Phase 3 Selinexor;Placebo
20 Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer Terminated NCT00016341 Phase 3 cisplatin;doxorubicin hydrochloride;megestrol acetate;paclitaxel;tamoxifen citrate
21 External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Completed NCT00376844 Phase 3
22 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
23 Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome Terminated NCT00566644 Phase 3
24 A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer Terminated NCT00883116 Phase 3 Ixabepilone;Doxorubicin;Paclitaxel
25 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
26 Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Completed NCT00003691 Phase 3 cisplatin;doxorubicin hydrochloride;paclitaxel
27 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
28 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
29 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
30 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed NCT01767155 Phase 3 AEZS-108 / zoptarelin doxorubicin;doxorubicin
31 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
32 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
33 Laparoscopic Approach to Cancer of the Endometrium Completed NCT00096408 Phase 3
34 Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer Terminated NCT00002976 Phase 3 conjugated estrogens
35 Regional Anesthesia and Endometrial Cancer Recurrence Withdrawn NCT00531349 Phase 3 Sevoflurane
36 Vaginal Cuff Brachytherapy Fractionation Study Recruiting NCT03785288 Phase 3
37 An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting NCT01697566 Phase 3 Metformin
38 Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer Recruiting NCT03241914 Phase 2, Phase 3 Megestrol Acetate
39 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Not yet recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
40 Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer Completed NCT02564276 Phase 3
41 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Recruiting NCT03517449 Phase 3 Pembrolizumab;Lenvatinib;Paclitaxel;Doxorubicin
42 Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. Recruiting NCT02598219 Phase 3 Pre-operative SN mapping with radionucleide;Intra-operative SN mapping with patent V blue dye;Intra-operative SN mapping with indocyanin green
43 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
44 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
45 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
46 Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC Recruiting NCT03463252 Phase 2, Phase 3 Progesterone;GnRH agonist
47 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
48 Tachosil for the Prevention of Symptomatic Lymph Cysts Completed NCT01470677 Phase 3 Tachosil fibrin patch
49 The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Recruiting NCT01820858 Phase 3 Paclitaxel;Paraplatin (Carboplatin Injection)
50 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) Recruiting NCT03884101 Phase 3 Lenvatinib;Paclitaxel;Carboplatin

Search NIH Clinical Center for Endometrial Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: endometrial neoplasms

Genetic Tests for Endometrial Cancer

Genetic tests related to Endometrial Cancer:

# Genetic test Affiliating Genes
1 Endometrial Carcinoma 30 CDH1 MLH3 MSH3 MSH6
2 Endometrial Neoplasm 30

Anatomical Context for Endometrial Cancer

MalaCards organs/tissues related to Endometrial Cancer:

42
Lymph Node, Uterus, Testes, Ovary, Endothelial, Colon, Cervix

The Foundational Model of Anatomy Ontology organs/tissues related to Endometrial Cancer:

20
The Tissue Lining The Uterus

Publications for Endometrial Cancer

Articles related to Endometrial Cancer:

(show top 50) (show all 7720)
# Title Authors Year
1
Gastric-type endocervical adenocarcinoma with uterine corpus involvement mimicking primary endometrial carcinoma. ( 31012190 )
2019
2
Impact of Coexisting Uterine Adenomyosis on the Survival Outcome of Patients with Endometrial Cancer: A Retrospective Cohort Study ( 31030493 )
2019
3
LncRNA NR2F1-AS1 is involved in the progression of endometrial cancer by sponging miR-363 to target SOX4. ( 31109400 )
2019
4
Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. ( 31109659 )
2019
5
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. ( 30935717 )
2019
6
SOX11 hypermethylation as a tumor biomarker in endometrial cancer. ( 30935961 )
2019
7
Oncogenic role of ABHD5 in endometrial cancer. ( 30936746 )
2019
8
A Prospective Observational Study Evaluating the Accuracy of MRI in Predicting the Extent of Disease in Endometrial Cancer. ( 30948904 )
2019
9
The potential predictive value of serum srCaS1 levels for overall survival in endometrial cancer. ( 30950002 )
2019
10
Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. ( 30952370 )
2019
11
Molecular expression characteristics confirm the malignancy concealed by morphological alterations in endometrial cancer after fertility-preserving treatment. ( 30953185 )
2019
12
ITE, an endogenous aryl hydrocarbon receptor ligand, suppresses endometrial cancer cell proliferation and migration. ( 30953668 )
2019
13
Cancer-Associated Fibroblasts Induce Epithelial-Mesenchymal Transition in Endometrial Cancer Cells by Regulating Pituitary Tumor Transforming Gene. ( 30961403 )
2019
14
Evaluation of changes in the expression pattern of EDIL3 in different grades of endometrial cancer Subtitle: EDIL3 in endometrial cancer. ( 30961491 )
2019
15
Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression. ( 30963412 )
2019
16
Evaluation of the French medical practices in endometrial cancer management by using quality indicators. ( 30965186 )
2019
17
Assessing the Role of Selenium in Endometrial Cancer Risk: A Mendelian Randomization Study. ( 30972295 )
2019
18
Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway. ( 30979588 )
2019
19
Neoadjuvant chemotherapy in patients with advanced endometrial cancer. ( 30980132 )
2019
20
A randomized controlled trial of WATAAP to promote physical activity in colorectal and endometrial cancer survivors. ( 30980691 )
2019
21
Sentinel Lymph Node Biopsies in Endometrial Cancer: Practice Patterns among Gynecologic Oncologists in the United States. ( 30980995 )
2019
22
miR-205-5p contributes to paclitaxel resistance and progression of endometrial cancer by downregulating FOXO1. ( 30982496 )
2019
23
Evolution of characteristics of women with endometrial cancer during a 40 years study period. ( 30986541 )
2019
24
TRIB3 suppresses proliferation and invasion and promotes apoptosis of endometrial cancer cells by regulating the AKT signaling pathway. ( 30988628 )
2019
25
Cyclin A is a reliable proliferation marker in endometrial cancer cell lines. ( 30988814 )
2019
26
Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. ( 30992185 )
2019
27
The Effect of Prognostic Factors and Adjuvant Radiotherapy on Survival in Patients with High-Grade Early-Stage Endometrial Cancer: A Retrospective Clinical Study. ( 30992424 )
2019
28
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. ( 30995174 )
2019
29
The impact of vaginal dilator use on vaginal stenosis and sexual quality of life in women treated with adjuvant radiotherapy for endometrial cancer. ( 30997541 )
2019
30
Delay in time to surgery and impact on survival in patients with endometrial cancer: A National Cancer Database Analysis. ( 31000472 )
2019
31
Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Inhibit Endometrial Cancer Cell Proliferation and Migration through Delivery of Exogenous miR-302a. ( 31001342 )
2019
32
Magnetic resonance imaging response in patients treated with definitive radiation therapy for medically inoperable endometrial cancer-Does it predict treatment response? ( 31005602 )
2019
33
Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer? ( 31005603 )
2019
34
miR-27b-3p/MARCH7 regulates invasion and metastasis of endometrial cancer cells through Snail-mediated pathway. ( 31006800 )
2019
35
Accuracy of frozen section at early clinical stage of endometrioid endometrial cancer: a retrospective analysis in Germany. ( 31006842 )
2019
36
Possible role of Thiazolidinedione in the management of Type-II Endometrial Cancer. ( 31010504 )
2019
37
Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience. ( 31011610 )
2019
38
The association of cancer-related fatigue with all-cause mortality of colorectal and endometrial cancer survivors: Results from the population-based PROFILES registry. ( 31012272 )
2019
39
Genome-wide DNA methylation analysis in obese women predicts an epigenetic signature for future endometrial cancer. ( 31015518 )
2019
40
Comparison of 3D conformal radiation therapy and intensity-modulated radiation therapy in patients with endometrial cancer: efficacy, safety and prognostic analysis. ( 31017032 )
2019
41
Role of less commonly agreed risk factors on disease recurrence in endometrial cancer: a propensity scorematched comparison. ( 31019841 )
2019
42
Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study. ( 31020889 )
2019
43
Sentinel lymph nodes (SLN) in endometrial cancer: The relationship between primary tumor histology, SLN metastasis size, and non-sentinel node metastasis. ( 31027899 )
2019
44
Lymph node dissection in endometrial cancer and clinical outcome: A population-based study in 5546 patients. ( 31027900 )
2019
45
The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression. ( 31028182 )
2019
46
Co-localization of Coagulation Factor X and its Inhibitory System, PZ/ZPI, in Human Endometrial Cancer Tissue. ( 31028196 )
2019
47
Impact of MDM2, TP53 and P14ARF Polymorphisms on Endometrial Cancer Risk and Onset. ( 31028217 )
2019
48
Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. ( 31029507 )
2019
49
Hepatoma-Derived Growth Factor and DDX5 Promote Carcinogenesis and Progression of Endometrial Cancer by Activating β-Catenin. ( 31032220 )
2019
50
A Novel Approach to Preoperative Risk Stratification in Endometrial Cancer: The Added Value of Immunohistochemical Markers. ( 31032226 )
2019

Variations for Endometrial Cancer

UniProtKB/Swiss-Prot genetic disease variations for Endometrial Cancer:

76
# Symbol AA change Variation ID SNP ID
1 PTEN p.His123Tyr VAR_026260 rs786204931

ClinVar genetic disease variations for Endometrial Cancer:

6 (show top 50) (show all 179)
# Gene Variation Type Significance SNP ID Assembly Location
1 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh37 Chromosome 1, 45798475: 45798475
2 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh38 Chromosome 1, 45332803: 45332803
3 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 GRCh37 Chromosome 1, 45797228: 45797228
4 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 GRCh38 Chromosome 1, 45331556: 45331556
5 MLH3 NM_001040108.1(MLH3): c.2221G> T (p.Val741Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs28756990 GRCh37 Chromosome 14, 75514138: 75514138
6 MLH3 NM_001040108.1(MLH3): c.2221G> T (p.Val741Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs28756990 GRCh38 Chromosome 14, 75047435: 75047435
7 MLH3 NM_001040108.1(MLH3): c.885delG (p.His296Thrfs) deletion Pathogenic GRCh38 Chromosome 14, 75048771: 75048771
8 MLH3 NM_001040108.1(MLH3): c.885delG (p.His296Thrfs) deletion Pathogenic GRCh37 Chromosome 14, 75515474: 75515474
9 PTEN NM_000314.6(PTEN): c.253+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs587776667 GRCh37 Chromosome 10, 89690847: 89690847
10 PTEN NM_000314.6(PTEN): c.253+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs587776667 GRCh38 Chromosome 10, 87931090: 87931090
11 MSH3 NM_002439.4(MSH3): c.1148delA (p.Lys383Argfs) deletion Pathogenic rs587776701 GRCh38 Chromosome 5, 80675103: 80675103
12 MSH3 NM_002439.4(MSH3): c.1148delA (p.Lys383Argfs) deletion Pathogenic rs587776701 GRCh37 Chromosome 5, 79970922: 79970922
13 CDH1 NM_004360.4(CDH1): c.2131C> G (p.Leu711Val) single nucleotide variant Uncertain significance rs121964871 GRCh37 Chromosome 16, 68857496: 68857496
14 CDH1 NM_004360.4(CDH1): c.2131C> G (p.Leu711Val) single nucleotide variant Uncertain significance rs121964871 GRCh38 Chromosome 16, 68823593: 68823593
15 CDH1 NM_004360.5(CDH1): c.1849G> A (p.Ala617Thr) single nucleotide variant Benign rs33935154 GRCh37 Chromosome 16, 68856041: 68856041
16 CDH1 NM_004360.5(CDH1): c.1849G> A (p.Ala617Thr) single nucleotide variant Benign rs33935154 GRCh38 Chromosome 16, 68822138: 68822138
17 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
18 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
19 KRAS NM_004985.4(KRAS): c.40G> A (p.Val14Ile) single nucleotide variant Pathogenic rs104894365 GRCh37 Chromosome 12, 25398279: 25398279
20 KRAS NM_004985.4(KRAS): c.40G> A (p.Val14Ile) single nucleotide variant Pathogenic rs104894365 GRCh38 Chromosome 12, 25245345: 25245345
21 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
22 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh38 Chromosome 10, 121520163: 121520163
23 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic rs121913478 GRCh37 Chromosome 10, 123274794: 123274794
24 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic rs121913478 GRCh38 Chromosome 10, 121515280: 121515280
25 FGFR2 NM_000141.4(FGFR2): c.1115C> G (p.Ser372Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913477 GRCh37 Chromosome 10, 123274803: 123274803
26 FGFR2 NM_000141.4(FGFR2): c.1115C> G (p.Ser372Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913477 GRCh38 Chromosome 10, 121515289: 121515289
27 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
28 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh38 Chromosome 3, 41224610: 41224610
29 MSH6 NM_000179.2(MSH6): c.3217C> T (p.Pro1073Ser) single nucleotide variant Uncertain significance rs142254875 GRCh37 Chromosome 2, 48030603: 48030603
30 MSH6 NM_000179.2(MSH6): c.3217C> T (p.Pro1073Ser) single nucleotide variant Uncertain significance rs142254875 GRCh38 Chromosome 2, 47803464: 47803464
31 MLH1 NM_000249.3(MLH1): c.1963A> G (p.Ile655Val) single nucleotide variant Likely benign rs55907433 GRCh37 Chromosome 3, 37090074: 37090074
32 MLH1 NM_000249.3(MLH1): c.1963A> G (p.Ile655Val) single nucleotide variant Likely benign rs55907433 GRCh38 Chromosome 3, 37048583: 37048583
33 PTEN NM_000314.7(PTEN): c.235G> A (p.Ala79Thr) single nucleotide variant Likely benign rs202004587 GRCh37 Chromosome 10, 89690828: 89690828
34 PTEN NM_000314.7(PTEN): c.235G> A (p.Ala79Thr) single nucleotide variant Likely benign rs202004587 GRCh38 Chromosome 10, 87931071: 87931071
35 MSH6 NM_000179.2(MSH6): c.2561A> T (p.Lys854Met) single nucleotide variant Uncertain significance rs34374438 GRCh37 Chromosome 2, 48027683: 48027683
36 MSH6 NM_000179.2(MSH6): c.2561A> T (p.Lys854Met) single nucleotide variant Uncertain significance rs34374438 GRCh38 Chromosome 2, 47800544: 47800544
37 MSH6 NM_000179.2(MSH6): c.2731C> T (p.Arg911Ter) single nucleotide variant Pathogenic rs63751017 GRCh37 Chromosome 2, 48027853: 48027853
38 MSH6 NM_000179.2(MSH6): c.2731C> T (p.Arg911Ter) single nucleotide variant Pathogenic rs63751017 GRCh38 Chromosome 2, 47800714: 47800714
39 MSH6 NM_000179.2(MSH6): c.3103C> T (p.Arg1035Ter) single nucleotide variant Pathogenic rs63749999 GRCh37 Chromosome 2, 48028225: 48028225
40 MSH6 NM_000179.2(MSH6): c.3103C> T (p.Arg1035Ter) single nucleotide variant Pathogenic rs63749999 GRCh38 Chromosome 2, 47801086: 47801086
41 MSH6 NM_000179.2(MSH6): c.3163G> A (p.Ala1055Thr) single nucleotide variant Uncertain significance rs587779254 GRCh37 Chromosome 2, 48028285: 48028285
42 MSH6 NM_000179.2(MSH6): c.3163G> A (p.Ala1055Thr) single nucleotide variant Uncertain significance rs587779254 GRCh38 Chromosome 2, 47801146: 47801146
43 MSH6 NM_000179.2(MSH6): c.3202C> T (p.Arg1068Ter) single nucleotide variant Pathogenic rs63749843 GRCh37 Chromosome 2, 48030588: 48030588
44 MSH6 NM_000179.2(MSH6): c.3202C> T (p.Arg1068Ter) single nucleotide variant Pathogenic rs63749843 GRCh38 Chromosome 2, 47803449: 47803449
45 MSH6 NM_000179.2(MSH6): c.3259C> T (p.Pro1087Ser) single nucleotide variant Uncertain significance rs63750998 GRCh37 Chromosome 2, 48030645: 48030645
46 MSH6 NM_000179.2(MSH6): c.3259C> T (p.Pro1087Ser) single nucleotide variant Uncertain significance rs63750998 GRCh38 Chromosome 2, 47803506: 47803506
47 MSH6 NM_000179.2(MSH6): c.3260C> G (p.Pro1087Arg) single nucleotide variant Uncertain significance rs63750753 GRCh37 Chromosome 2, 48030646: 48030646
48 MSH6 NM_000179.2(MSH6): c.3260C> G (p.Pro1087Arg) single nucleotide variant Uncertain significance rs63750753 GRCh38 Chromosome 2, 47803507: 47803507
49 MSH6 NM_000179.2(MSH6): c.3299C> T (p.Thr1100Met) single nucleotide variant Uncertain significance rs63750442 GRCh37 Chromosome 2, 48030685: 48030685
50 MSH6 NM_000179.2(MSH6): c.3299C> T (p.Thr1100Met) single nucleotide variant Uncertain significance rs63750442 GRCh38 Chromosome 2, 47803546: 47803546

Cosmic variations for Endometrial Cancer:

9 (show top 50) (show all 4215)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6935601 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.1124G>T p.S375I 23:15822917-15822917 0
2 COSM6982868 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.854C>A p.S285Y 23:15820233-15820233 0
3 COSM6935600 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.514T>A p.C172S 23:15809275-15809275 0
4 COSM6845183 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2143C>T p.R715* 16:72958003-72958003 0
5 COSM6845146 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8961G>T p.K2987N 16:72793721-72793721 0
6 COSM6845174 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4129C>A p.L1377I 16:72798553-72798553 0
7 COSM973503 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8152G>A p.A2718T 16:72794530-72794530 0
8 COSM6845142 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3504G>T p.E1168D 16:72829804-72829804 0
9 COSM6845190 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9555A>C p.Q3185H 16:72788721-72788721 0
10 COSM1709385 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3925C>T p.R1309* 16:72800069-72800069 0
11 COSM6845133 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2740G>A p.D914N 16:72950945-72950945 0
12 COSM6845164 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7666G>C p.A2556P 16:72795016-72795016 0
13 COSM6845182 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3628C>T p.R1210* 16:72811940-72811940 0
14 COSM6845156 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2875G>A p.D959N 16:72950810-72950810 0
15 COSM973493 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9001G>T p.E3001* 16:72793681-72793681 0
16 COSM6826430 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8002C>T p.R2668* 16:72794680-72794680 0
17 COSM6845155 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2725G>A p.G909S 16:72950960-72950960 0
18 COSM1233352 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6446G>A p.R2149H 16:72796236-72796236 0
19 COSM6826396 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.568G>A p.V190M 16:72959578-72959578 0
20 COSM6845159 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3829G>A p.V1277M 16:72811612-72811612 0
21 COSM5563443 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6820C>T p.Q2274* 16:72795862-72795862 0
22 COSM6845186 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9266A>C p.E3089A 16:72793416-72793416 0
23 COSM6984593 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6046G>A p.E2016K 16:72796636-72796636 0
24 COSM973492 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9006G>T p.K3002N 16:72793676-72793676 0
25 COSM6984595 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5623G>A p.E1875K 16:72797059-72797059 0
26 COSM973535 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4316G>A p.R1439Q 16:72798366-72798366 0
27 COSM6845141 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1969G>A p.G657S 16:72958177-72958177 0
28 COSM6845171 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3115C>T p.H1039Y 16:72950570-72950570 0
29 COSM6845173 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3863C>T p.T1288M 16:72811578-72811578 0
30 COSM6982810 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4103A>G p.N1368S 16:72798579-72798579 0
31 COSM1640552 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8849G>A p.R2950H 16:72793833-72793833 0
32 COSM6982809 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4406C>T p.A1469V 16:72798276-72798276 0
33 COSM6984596 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1378G>A p.E460K 16:72958768-72958768 0
34 COSM6845169 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5125G>T p.E1709* 16:72797557-72797557 0
35 COSM6845189 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8228A>G p.Y2743C 16:72794454-72794454 0
36 COSM1379731 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.884G>A p.R295H 16:72959262-72959262 0
37 COSM3276890 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3397G>A p.E1133K 16:72889782-72889782 0
38 COSM3276999 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.359G>A p.G120E 16:72959787-72959787 0
39 COSM6845185 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5635A>T p.K1879* 16:72797047-72797047 0
40 COSM6845129 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7559T>C p.L2520P 16:72795123-72795123 0
41 COSM6845179 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8576C>T p.T2859M 16:72794106-72794106 0
42 COSM973560 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1115G>A p.R372Q 16:72959031-72959031 0
43 COSM6845161 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5754G>T p.K1918N 16:72796928-72796928 0
44 COSM6845178 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8197C>A p.R2733S 16:72794485-72794485 0
45 COSM6845165 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 0
46 COSM6845188 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6058A>G p.K2020E 16:72796624-72796624 0
47 COSM6984594 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5941G>A p.E1981K 16:72796741-72796741 0
48 COSM6845127 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4274T>C p.I1425T 16:72798408-72798408 0
49 COSM973483 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.10750G>A p.A3584T 16:72787526-72787526 0
50 COSM6845170 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.338C>T p.A113V 16:72959808-72959808 0

Copy number variations for Endometrial Cancer from CNVD:

7 (show top 50) (show all 66)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14799 1 110230418 110236367 Duplication GSTM1 Endometrial cancer
2 16430 1 124300000 247249719 Gain Endometrial cancer
3 16431 1 124300000 247249719 Gain Endometrial cancer
4 16443 1 124300000 247249719 Gain or loss Endometrial cancer
5 30005 1 23900000 28000000 Copy number STMN1 Endometrial cancer
6 38170 10 1 40300000 Gain Endometrial cancer
7 38173 10 1 40300000 Gain or loss Endometrial cancer
8 42809 10 40300000 135374737 Gain Endometrial cancer
9 42810 10 40300000 135374737 Gain or loss Endometrial cancer
10 47133 10 89613174 89718512 Copy number PTEN Endometrial cancer
11 47161 10 89623194 89728531 Loss PTEN Endometrial cancer
12 48495 11 1 52900000 Gain or loss Endometrial cancer
13 55432 11 52900000 134452384 Gain or loss Endometrial cancer
14 61536 12 1 35400000 Gain or loss Endometrial cancer
15 66123 12 25358179 25403863 Amplification KRAS Endometrial cancer
16 75150 13 16000000 114142980 Gain or loss Endometrial cancer
17 82814 14 15600000 106368585 Gain or loss Endometrial cancer
18 89241 15 17000000 100338915 Gain or loss Endometrial cancer
19 97274 16 1 38200000 Gain Endometrial cancer
20 97276 16 1 38200000 Gain or loss Endometrial cancer
21 101463 16 38200000 88827254 Gain or loss Endometrial cancer
22 106793 17 1 22200000 Gain or loss Endometrial cancer
23 108760 17 22200000 78774742 Gain or loss Endometrial cancer
24 119170 18 1 16100000 Gain or loss Endometrial cancer
25 119734 18 16100000 76117153 Gain or loss Endometrial cancer
26 124098 19 1 28500000 Gain or loss Endometrial cancer
27 127175 19 28500000 63811651 Gain or loss Endometrial cancer
28 134355 2 1 93300000 Gain or loss Endometrial cancer
29 146256 2 47483766 47760012 Rearrangement MSH2 Endometrial cancer
30 149784 2 93300000 242951149 Gain or loss Endometrial cancer
31 150416 20 1 27100000 Gain or loss Endometrial cancer
32 151944 20 27100000 62435964 Gain Endometrial cancer
33 151953 20 27100000 62435964 Gain or loss Endometrial cancer
34 157114 21 12300000 46944323 Gain or loss Endometrial cancer
35 160291 22 11800000 49691432 Gain or loss Endometrial cancer
36 163141 22 24376139 24384284 Duplication GSTT1 Endometrial cancer
37 166155 3 1 91700000 Gain or loss Endometrial cancer
38 172027 3 175700000 179000000 Amplification PIK3CA Endometrial cancer
39 175016 3 37009982 37067341 Rearrangement MLH1 Endometrial cancer
40 179466 3 91700000 199501827 Gain or loss Endometrial cancer
41 179984 4 1 50700000 Gain or loss Endometrial cancer
42 187532 4 50700000 191273063 Gain or loss Endometrial cancer
43 200012 5 47700000 180857866 Gain or loss Endometrial cancer
44 203699 6 1 60500000 Gain or loss Endometrial cancer
45 214470 6 60500000 170899992 Gain or loss Endometrial cancer
46 217117 7 1 59100000 Gain or loss Endometrial cancer
47 226563 7 59100000 158821424 Gain or loss Endometrial cancer
48 230833 8 1 45200000 Gain or loss Endometrial cancer
49 240068 8 45200000 146274826 Gain Endometrial cancer
50 240080 8 45200000 146274826 Gain or loss Endometrial cancer

Expression for Endometrial Cancer

Search GEO for disease gene expression data for Endometrial Cancer.

Pathways for Endometrial Cancer

Pathways related to Endometrial Cancer according to KEGG:

38
# Name Kegg Source Accession
1 Endometrial cancer hsa05213

Pathways related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 CDH1 CTNNB1 FGFR2 KRAS MSH3 MSH6
2
Show member pathways
12.47 CDH1 CTNNB1 FGFR2 KRAS PTEN
3
Show member pathways
12.43 CDH1 FGFR2 KRAS MSH6 PTEN
4 11.94 CDH1 CTNNB1 KRAS MSH3 MSH6
5 11.89 CDH1 CTNNB1 FGFR2 KRAS MSH3 MSH6
6 11.76 CTNNB1 KRAS PTEN
7 11.73 CTNNB1 KRAS PTEN
8 11.68 CDH1 CTNNB1 FGFR2
9
Show member pathways
11.64 MLH3 MSH3 MSH6
10 11.54 CDH1 CTNNB1 KRAS MSH6 PTEN
11 11.36 FGFR2 KRAS PTEN
12 10.57 CDH1 CTNNB1
13 10.41 HOTAIR LINC-ROR UCA1

GO Terms for Endometrial Cancer

Cellular components related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
2 mismatch repair complex GO:0032300 8.8 MLH3 MSH3 MSH6

Biological processes related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of endothelial cell differentiation GO:0045603 9.55 CTNNB1 MIR200C
2 epithelial tube branching involved in lung morphogenesis GO:0060441 9.54 CTNNB1 KRAS
3 negative regulation of DNA recombination GO:0045910 9.52 MSH3 MSH6
4 regulation of osteoblast differentiation GO:0045667 9.51 CTNNB1 FGFR2
5 regulation of synaptic transmission, GABAergic GO:0032228 9.49 KRAS PTEN
6 morphogenesis of embryonic epithelium GO:0016331 9.48 CTNNB1 FGFR2
7 entry of bacterium into host cell GO:0035635 9.46 CDH1 CTNNB1
8 lung-associated mesenchyme development GO:0060484 9.43 CTNNB1 FGFR2
9 positive regulation of helicase activity GO:0051096 9.4 MSH3 MSH6
10 replication fork arrest GO:0043111 9.37 MSH3 MSH6
11 cellular response to indole-3-methanol GO:0071681 9.32 CDH1 CTNNB1
12 maintenance of DNA repeat elements GO:0043570 9.26 MSH3 MSH6
13 meiotic mismatch repair GO:0000710 9.16 MSH3 MSH6
14 mesenchymal cell proliferation involved in lung development GO:0060916 8.96 CTNNB1 FGFR2
15 mismatch repair GO:0006298 8.92 MLH3 MSH3 MSH6 MUTYH

Molecular functions related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MutLalpha complex binding GO:0032405 9.37 MSH6 MUTYH
2 guanine/thymine mispair binding GO:0032137 9.32 MSH3 MSH6
3 single thymine insertion binding GO:0032143 9.26 MSH3 MSH6
4 single guanine insertion binding GO:0032142 9.16 MSH3 MSH6
5 mismatched DNA binding GO:0030983 9.13 MLH3 MSH3 MSH6
6 centromeric DNA binding GO:0019237 9.1 MLH3
7 oxidized purine DNA binding GO:0032357